Fred Hirsch, MD, PhD
Professor Adjoint, Medicine-Medical Oncology

Publications

  • Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker E, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Marc Ladanyi, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018 Jan 23. [Epub ahead of print] PubMed PMID: 29398453
  • Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker E, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018 Jan 23. [Epub ahead of print] PubMed PMID: 29396253
  • Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker E, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Jan 22. [Epub ahead of print] PubMed PMID: 29355391
  • Ren S, Zhang S, Jiang T, He Y, Ma Z, Cai H, Xu X, Li Y, Cai W, Zhou J, Liu X, Hu X, Zhang J, Yu H, Zhou C, Hirsch FR. Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology. 2018;7(2):e1384108. PubMed PMID: 29308305
  • Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr., Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 Feb;13(2):165-183. PubMed PMID: 29175116
  • Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 Jan;19(1):101-114. PubMed PMID: 29169877
  • Genova C, Socinski MA, Hozak RR, Mi G, Kurek R, Shahidi J, Paz-Ares L, Thatcher N, Rivard CJ, Varella-Garcia M, Hirsch FR. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. J Thorac Oncol. 2018 Feb;13(2):228-236. PubMed PMID: 29158193
  • Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA. Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol. 2018 Feb;13(2):205-217. PubMed PMID: 29127023
  • West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 Jan;19(1):84-92. PubMed PMID: 28801183
  • He Y, Yang Y, Kuang P, Ren S, Rozeboom L, Rivard CJ, Li X, Zhou C, Hirsch FR. Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules. Onco Targets Ther. 2017;10:5915-5926. PubMed PMID: 29263681
  • Kong FS, Hirsch FR, Machtay M. Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer. Transl Lung Cancer Res. 2017 Dec;6(6):713-715. PubMed PMID: 29218273
  • He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. MHC class II expression in lung cancer. Lung Cancer. 2017 Oct;112:75-80. PubMed PMID: 29191604
  • Jiang T, Li X, Wang J, Su C, Han W, Zhao C, Wu F, Gao G, Li W, Chen X, Li J, Zhou F, Zhao J, Cai W, Zhang H, Du B, Zhang J, Ren S, Zhou C, Yu H, Hirsch FR. Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics. 2017;7(19):4753-4762. PubMed PMID: 29187901
  • Suda K, Rozeboom L, Furugaki K, Yu H, Melnick MAC, Ellison K, Rivard CJ, Politi K, Mitsudomi T, Hirsch FR. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. Biomed Res Int. 2017;2017:7694202. PubMed PMID: 29119113
  • Rao S, Sigl V, Wimmer RA, Novatchkova M, Jais A, Wagner G, Handschuh S, Uribesalgo I, Hagelkruys A, Kozieradzki I, Tortola L, Nitsch R, Cronin SJ, Orthofer M, Branstetter D, Canon J, Rossi J, D'Arcangelo M, Botling J, Micke P, Fleur L, Edlund K, Bergqvist M, Ekman S, Lendl T, Popper H, Takayanagi H, Kenner L, Hirsch FR, Dougall W, Penninger JM. RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. Genes Dev. 2017 Oct 15;31(20):2099-2112. PubMed PMID: 29118048
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov;24(6):311-335. PubMed PMID: 28777143
  • Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep;24(5):235-251. PubMed PMID: 28777142
  • Hirsch FR. Programmed death ligand 1 testing: is there one best test?. Clin Adv Hematol Oncol. 2017 Jun;15(6):438-440. PubMed PMID: 28749902
  • Suda K, Rivard CJ, Mitsudomi T, Hirsch FR. Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Rev Anticancer Ther. 2017 Sep;17(9):779-786. PubMed PMID: 28701107
  • Li X, Cai W, Yang G, Su C, Ren S, Zhao C, Hu R, Chen X, Gao G, Guo Z, Li W, Zhou C, Hirsch FR. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. J Thorac Oncol. 2017 Sep;12(9):1388-1397. PubMed PMID: 28624467
  • Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 Aug;12(8):1183-1209. PubMed PMID: 28579481
  • Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017 Jul;109:1-8. PubMed PMID: 28577937
  • Hirsch FR, Zaric B, Rabea A, Thongprasert S, Lertprasertsuke N, Dalurzo ML, Varella-Garcia M. Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. Am Soc Clin Oncol Educ Book. 2017;37:403-408. PubMed PMID: 28561679
  • Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H. Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. Clin Lung Cancer. 2017 Nov;18(6):640-650.e2. PubMed PMID: 28522158
  • Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight. 2017 Mar 23;2(6):e90449. PubMed PMID: 28352657
  • Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Aug 1;3(8):1051-1058. PubMed PMID: 28278348
  • He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, Zhou C, Hirsch FR. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Med Sci Monit. 2017 Mar 9;23:1208-1216. PubMed PMID: 28275222
  • Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. J Thorac Oncol. 2017 Jun;12(6):1015-1020. PubMed PMID: 28193529
  • Suda K, Rozeboom L, Yu H, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS One. 2017;12(2):e0172209. PubMed PMID: 28192473
  • He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol. 2017 May;12(5):814-823. PubMed PMID: 28132868
  • McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland Å, Hirsch FR, Brustugun OT. PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. Lung Cancer. 2017 Jan;103:52-57. PubMed PMID: 28024696
  • Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017 Feb;12(2):208-222. PubMed PMID: 27913228
  • Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, Rivard CJ, Dziadziuszko R, Zhou C, Hussein M, Richards D, Wilks S, Monte M, Edenfield W, Goldschmidt J, Page R, Ulrich B, Waterhouse D, Close S, Jassem J, Kulig K, Hirsch FR. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. J Thorac Oncol. 2017 Jan;12(1):110-120. PubMed PMID: 27639678
  • Suda K, Bunn PA Jr, Rivard CJ, Mitsudomi T, Hirsch FR. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. J Thorac Oncol. 2017 Jan;12(1):27-35. PubMed PMID: 27642065
  • Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017 Jan 21;389(10066):299-311. PubMed PMID: 27574741
  • Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):43-49. PubMed PMID: 27461773
  • Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clin Lung Cancer. 2017 Jan;18(1):e71-e79. PubMed PMID: 27426974
  • Bunn PA Jr, Minna J, Augustyn A, Gazdar A, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier J, Byers LA, Wynes MW, McFadden D, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock C, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?. J Thorac Oncol. 2016 Jan 29. [Epub ahead of print] PubMed PMID: 26829312
  • He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, Li X, Li J, Zhou C, Hirsch FR. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Med Sci Monit. 2016 Jan 26;22:276-83. PubMed PMID: 26811313
  • Kerr KM, Hirsch FR. Programmed Death Ligand 1 Immunohistochemistry: Friend or Foe?. Arch Pathol Lab Med. 2016 Jan 12. [Epub ahead of print] PubMed PMID: 26756647
  • Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. PubMed PMID: 26542061
  • Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar;38(3):439-47. PubMed PMID: 25352401
  • Yu H, He Y, Rivard C, Chan D, Gao D, Ellison K, Rozeboom L, Suda K, Hirsch F. PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines: Topic: Pathology. J Thorac Oncol. 2016 Nov;11(11S):S281. PubMed PMID: 27969487
  • Gaspar LE, Mornex F, Kong FS, Hirsch F. MINI01.15: Prophylactic Cranial Irradiation (PCI) for Limited Small Cell Lung Cancer (LSCLC): An IASLC Physician Survey: Topic: Radiation Oncology. J Thorac Oncol. 2016 Nov;11(11S):S265-S266. PubMed PMID: 27969462
  • Rimm D, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Hirsch F, Wistuba II. ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology. J Thorac Oncol. 2016 Nov;11(11S):S249. PubMed PMID: 27969440
  • Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 Dec;11(12):2066-2081. PubMed PMID: 27575423
  • Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. Onco Targets Ther. 2016 Aug 31;9:5427-37. PubMed PMID: 27621656
  • Hirsch FR, Suda K, Wiens J, Bunn PA Jr. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016 Sep 3;388(10048):1012-24. PubMed PMID: 27598681
  • Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2016 Aug 26. [Epub ahead of print] PubMed PMID: 27574741
  • Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 Aug;11(8):1246-62. PubMed PMID: 27453164
  • Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. J Thorac Oncol. 2016 Sep;11(9):1387-96. PubMed PMID: 27401214
  • Gazdar AF, Hirsch FR, Minna JD. Correction: "From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers". J Thorac Oncol. 2016 Jul;11(7):e88-9. PubMed PMID: 27339412
  • He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C, Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016 Sep;107(9):1193-7. PubMed PMID: 27297395
  • Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 Sep;11(9):1411-22. PubMed PMID: 27296106
  • Suda K, Murakami I, Yu H, Ellison K, Shimoji M, Genova C, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. J Thorac Oncol. 2016 Oct;11(10):1711-7. PubMed PMID: 27257133
  • Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. PubMed PMID: 27229180
  • Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. cMET Exon 14 Skipping: From the Structure to the Clinic. J Thorac Oncol. 2016 Sep;11(9):1423-32. PubMed PMID: 27223456
  • Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Kurek R, Varella-Garcia M, Thatcher N, Hirsch FR. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol. 2016 Aug;27(8):1573-9. PubMed PMID: 27207107
  • Paz-Ares L, Socinski MA, Shahidi J, Hozak RR, Soldatenkova V, Thatcher N, Hirsch F. 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Thorac Oncol. 2016 Apr;11(4 Suppl):S153. PubMed PMID: 27198355
  • Suda K, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. Cancer Res. 2016 May 15;76(10):3109-10. PubMed PMID: 27197234
  • He Y, Sun W, Wang Y, Ren S, Li X, Li J, Rivard CJ, Zhou C, Hirsch FR. Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. Onco Targets Ther. 2016 Apr 21;9:2409-14. PubMed PMID: 27143936
  • Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016 Jul;11(7):964-75. PubMed PMID: 27117833
  • Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2016 Jun;11(3):429. PubMed PMID: 27056749
  • Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May;11(5):613-38. PubMed PMID: 27013409
  • Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. J Thorac Oncol. 2016 Apr;11(4):453-74. PubMed PMID: 26829312
  • He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, Li X, Li J, Zhou C, Hirsch FR. Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. Med Sci Monit. 2016 Jan 26;22:276-83. PubMed PMID: 26811313
  • Kerr KM, Hirsch FR. Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. Arch Pathol Lab Med. 2016 Apr;140(4):326-31. PubMed PMID: 26756647
  • Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar;11(3):420-5. PubMed PMID: 26725184
  • Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol. 2016 Mar;11(3):287-99. PubMed PMID: 26723239
  • Gandara DR, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar;2(3):300-1. PubMed PMID: 26720042
  • Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. J Clin Neurosci. 2016 Apr;26:46-9. PubMed PMID: 26677785
  • Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA. Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. PubMed PMID: 26542061
  • Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar;38(3):439-47. PubMed PMID: 25352401
  • Ritter L, Götz G, Sorge I, Lehnert T, Hirsch FW, Bühligen U, Vieweger A, Geyer C. Significance of MR Angiography in the Diagnosis of Aberrant Renal Arteries as the Cause of Ureteropelvic Junction Obstruction in Children. Rofo. 2015 Jan;187(1):42-48. PubMed PMID: 25226231
  • Preuß M, Thome U, Kluge J, Hirsch FW, Viehweger A, Nestler U. Retroclival arachnoid cyst in a preterm infant after ventriculitis and intraventricular hemorrhage-a case report. Childs Nerv Syst. 2015 Feb;31(2):347-50. PubMed PMID: 25108562
  • Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2015 Dec 24. [Epub ahead of print] PubMed PMID: 26725184
  • Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. J Thorac Oncol. 2015 Dec 24. [Epub ahead of print] PubMed PMID: 26723239
  • Gandara DR, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2015 Dec 30;:1-2. [Epub ahead of print] PubMed PMID: 26720042
  • Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. J Clin Neurosci. 2015 Dec 8. [Epub ahead of print] PubMed PMID: 26677785
  • Hirsch FR, Bunn PA Jr. Chemotherapy: Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. Nat Rev Clin Oncol. 2015 Dec;12(12):689-90. PubMed PMID: 26552954
  • Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma. J Clin Oncol. 2015 Nov 10;33(32):3701-9. PubMed PMID: 26416997
  • Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. Oncologist. 2015 Oct;20(10):1175-81. PubMed PMID: 26330460
  • Soulières D, Hirsch FR, Shepherd FA, Bordogna W, Delmar P, Shames DS, Klughammer B. PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Sep;10(9):1364-9. PubMed PMID: 26291013
  • Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-60. PubMed PMID: 26291008
  • Rikke BA, Wynes MW, Rozeboom LM, Barón AE, Hirsch FR. Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. Biomark Med. 2015;9(8):751-61. PubMed PMID: 26223535
  • Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015 Sep 15;6(27):23582-93. PubMed PMID: 26160838
  • Hirsch FR, Herbst RS, Gandara DR. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncol. 2015 Aug;16(8):872-3. PubMed PMID: 26156654
  • Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):1067-75. PubMed PMID: 26134224
  • Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. J Thorac Oncol. 2015 Jul;10(7):985-9. PubMed PMID: 26134220
  • Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. PubMed PMID: 26045340
  • Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, Dziadziuszko R, Jassem J, Varella-Garcia M, Heasley LE, Kowalewski AA, Ellison K, Chen G, Zhou C, Hirsch FR. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul;10(7):1083-90. PubMed PMID: 26020126
  • Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Maessenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, Eagles JR, Hirsch FR, Van Bremen T, Bootz F, Schroeck A, Kim J, Tan AC, Jimeno A, Heasley LE, Perner S. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res. 2015 Oct 1;21(19):4356-64. PubMed PMID: 26015511
  • Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2015 Dec;10(4):583-96. PubMed PMID: 26004768
  • Gandara DR, Hammerman PS, Sos ML, Lara PN Jr, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15;21(10):2236-43. PubMed PMID: 25979930
  • Hornberger J, Hirsch FR, Li Q, Page RD. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial. Lung Cancer. 2015 May;88(2):223-30. PubMed PMID: 25804732
  • Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015 Mar 4. [Epub ahead of print] PubMed PMID: 25740387
  • Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, Ilouze M, Dvir A, Boyle T, Wynes M, Miller VA, Lipson D, Palmer GA, Ali SM, Dekel S, Brenner R, Bunn PA Jr, Peled N. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015 Mar;20(3):316-22. PubMed PMID: 25721120
  • Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015 Mar;16(3):328-37. PubMed PMID: 25701171
  • Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 1;21(7):1514-24. PubMed PMID: 25680375
  • Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May;97(5):488-91. PubMed PMID: 25676724
  • Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015 Mar;16(2):106-11. PubMed PMID: 25467930
  • Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Mar;9(3):e21-3. PubMed PMID: 24518095
  • Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan;2(1):19-21. PubMed PMID: 24461890
  • Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD, International Association for the Study of Lung Cancer Strategic Screening Advisory Committee. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. J Thorac Oncol. 2014 Feb;9(2):141-3. PubMed PMID: 24419409
  • Hirsch FR, Jotte RM, Berry CA, Mencia WA, Stowell SA, Gardner AJ. Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. Cancer Control. 2014 Jan;21(1):90-7. PubMed PMID: 24357747
  • Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH Jr, Welch JJ, Korn EL, Ullmann CD, Hirsch FR. Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. J Thorac Oncol. 2014 Oct;9(10):1443-8. PubMed PMID: 25521397
  • Hirsch FR. International Association for the Study of Lung Cancer (IASLC): celebrating 40 years with scientific and educational achievements!. J Thorac Oncol. 2014 Oct;9(10):1424-5. PubMed PMID: 25521396
  • Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 Immunohistochemistry Among Major Genotypes of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2014 Oct 24. [Epub ahead of print] PubMed PMID: 25467930
  • Tsao MS, Travis WD, Brambilla E, Nicholson AG, Noguchi M, Hirsch FR, IASLC Pathology Committee. Forty years of the international association for study of lung cancer pathology committee. J Thorac Oncol. 2014 Dec;9(12):1740-9. PubMed PMID: 25393791
  • Hoppmann J, Wagner IV, Junghans G, Wudy SA, Buchfelder M, Hirsch FW, Ritter L, Kiess W, Pfäffle R. How early can one diagnose Cushing's disease? An early diagnosis in a case of prepubertal Cushing's disease. J Pediatr Endocrinol Metab. 2014 Nov;27(11-12):1043-7. PubMed PMID: 25367688
  • Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2014 Oct 29. [Epub ahead of print] PubMed PMID: 25352401
  • Li J, Li X, Ren S, Chen X, Zhang Y, Zhou F, Zhao M, Zhao C, Chen X, Cheng N, Zhao Y, Zhou C, Hirsch FR. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 2014 Sep 15;5(17):7902-16. PubMed PMID: 25277203
  • Thunnissen E, Noguchi M, Aisner S, Beasley MB, Brambilla E, Chirieac LR, Chung JH, Dacic S, Geisinger KR, Hirsch FR, Ishikawa Y, Kerr KM, Lantejoul S, Matsuno Y, Minami Y, Moreira AL, Pelosi G, Petersen I, Roggli V, Travis WD, Wistuba I, Yatabe Y, Dziadziuszko R, Witte B, Tsao MS, Nicholson AG. Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol. 2014 Sep;9(9):1354-62. PubMed PMID: 25122431
  • Hirsch FR, Bunn PA Jr, Herbst RS. "Companion diagnostics": has their time come and gone?. Clin Cancer Res. 2014 Sep 1;20(17):4422-4. PubMed PMID: 25059519
  • Komaki R, Paulus R, Blumenschein GR Jr, Curran WJ Jr, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul;112(1):30-6. PubMed PMID: 25042878
  • Coleman CH, Ardiot C, Blesson S, Bonnin Y, Bompart F, Colonna P, Dhai A, Ecuru J, Edielu A, Hervé C, Hirsch F, Kouyaté B, Mamzer-Bruneel MF, Maoundé D, Martinent E, Ntsiba H, Pelé G, Quéva G, Reinmund MC, Sarr SC, Sepou A, Tarral A, Tetimian D, Valverde O, Van Nieuwenhove S, Strub-Wourgaft N. Improving the Quality of Host Country Ethical Oversight of International Research: The Use of a Collaborative 'Pre-Review' Mechanism for a Study of Fexinidazole for Human African Trypanosomiasis. Dev World Bioeth. 2014 Jul 14. [Epub ahead of print] PubMed PMID: 25039421
  • Christoph DC, Reyna-Asuncion B, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Gauler TC, Wohlschlaeger J, Schuler M, Eberhardt WE, Hirsch FR. Assessment of folate receptor-a and epidermal growth factor receptor expression in pemetrexed-treated non-small-cell lung cancer patients. Clin Lung Cancer. 2014 Sep;15(5):320-30.e1-3. PubMed PMID: 24993594
  • Di Maio M, De Marinis F, Hirsch FR, Gridelli C. Diagnostic and therapeutic issues for patients with advanced non-small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review). Int J Oncol. 2014 Aug;45(2):509-15. PubMed PMID: 24859689
  • D'Arcangelo M, Hirsch FR. Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics. 2014;8:183-92. PubMed PMID: 24790411
  • Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014 Jun 15;20(12):3299-309. PubMed PMID: 24771645
  • Purz S, Sabri O, Viehweger A, Barthel H, Kluge R, Sorge I, Hirsch FW. Potential Pediatric Applications of PET/MR. J Nucl Med. 2014 Apr 24;55(Supplement 2):32S-39S. [Epub ahead of print] PubMed PMID: 24762622
  • Zhao M, Zhang Y, Cai W, Li J, Zhou F, Cheng N, Ren R, Zhao C, Li X, Ren S, Zhou C, Hirsch FR. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 2014 Aug 1;120(15):2299-307. PubMed PMID: 24737648
  • Wynes MW, Sholl LM, Dietel M, Schuuring E, Tsao MS, Yatabe Y, Tubbs RR, Hirsch FR. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol. 2014 May;9(5):631-8. PubMed PMID: 24722153
  • Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW, Fritzsch D, Hoffmann KT, Bernhard MK, Sabri O. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Childs Nerv Syst. 2014 Aug;30(8):1399-403. PubMed PMID: 24710719
  • Bunn PA Jr, Hirsch FR, Aisner DL. Is there clinical value to prognostic signatures in early-stage NSCLC?. Clin Cancer Res. 2014 Apr 1;20(7):1727-9. PubMed PMID: 24583801
  • Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J Thorac Oncol. 2014 Mar;9(3):e21-3. PubMed PMID: 24518095
  • Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May;15(3):173-81. PubMed PMID: 24486058
  • Czaplik M, Bergrath S, Rossaint R, Thelen S, Brodziak T, Valentin B, Hirsch F, Beckers SK, Brokmann JC. Employment of telemedicine in emergency medicine. Clinical requirement analysis, system development and first test results. Methods Inf Med. 2014;53(2):99-107. PubMed PMID: 24477815
  • Hirsch FR, Bunn PA Jr. Progress in research on screening and genetics in lung cancer. Lancet Respir Med. 2014 Jan;2(1):19-21. PubMed PMID: 24461890
  • Field JK, Aberle DR, Altorki N, Baldwin DR, Dresler C, Duffy SW, Goldstraw P, Hirsch FR, Pedersen JH, de Koning HJ, Mulshine JL, Sullivan DC, Tsao MS, Travis WD, International Association for the Study of Lung Cancer Strategic Screening Advisory Committee. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. J Thorac Oncol. 2014 Feb;9(2):141-3. PubMed PMID: 24419409
  • Hirsch FR, Jotte RM, Berry CA, Mencia WA, Stowell SA, Gardner AJ. Quality of care of patients with non-small-cell lung cancer: a report of a performance improvement initiative. Cancer Control. 2014 Jan;21(1):90-7. PubMed PMID: 24357747
  • Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2013 Dec 27. [Epub ahead of print] PubMed PMID: 24486058
  • Peled N, Zach L, Liran O, Ilouze M, Bunn PA Jr, Hirsch FR. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. J Thorac Oncol. 2013 Dec;8(12):e112-3. PubMed PMID: 24389447
  • Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol. 2013 Dec;8(12):1492-501. PubMed PMID: 24389431
  • Hirsch FR. Squamous cell lung cancer: where do we stand and where are we going?. Oncology (Williston Park). 2013 Sep;27(9):914-5. PubMed PMID: 24282990
  • Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec;8(12):1519-28. PubMed PMID: 24189513
  • Göke F, Göke A, von Mässenhausen A, Franzen A, Sharma R, Kirsten R, Böhm D, Kristiansen G, Stenzinger A, Wynes M, Hirsch FR, Weichert W, Heasley L, Buettner R, Perner S. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 2013;88(3):172-81. PubMed PMID: 24135816
  • Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013;3:219. PubMed PMID: 24010120
  • Kelly K, Chansky K, Mack PC, Lara PN Jr, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov;14(6):627-35. PubMed PMID: 23910067
  • Hirsch FR, Gandara DR. FASTACT-2: but don't act too fast. Lancet Oncol. 2013 Jul;14(8):684-5. PubMed PMID: 23782815
  • Peled N, Wynes MW, Ikeda N, Ohira T, Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C, Hirsch FR. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cell Oncol (Dordr). 2013 Jul;36(4):277-88. PubMed PMID: 23619944
  • Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug;7(4):776-90. PubMed PMID: 23607916
  • Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013 Jun 1;73(11):3381-92. PubMed PMID: 23576557
  • Peled N, Barash O, Tisch U, Ionescu R, Broza YY, Ilouze M, Mattei J, Bunn PA Jr, Hirsch FR, Haick H. Volatile fingerprints of cancer specific genetic mutations. Nanomedicine. 2013 Aug;9(6):758-66. PubMed PMID: 23428987
  • Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul;14(4):351-5. PubMed PMID: 23415808
  • Zielinski C, Knapp S, Mascaux C, Hirsch F. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol. 2013 May;24(5):1170-9. PubMed PMID: 23393121
  • D'Arcangelo M, Wynes MW, Hirsch FR. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer. Curr Opin Oncol. 2013 Mar;25(2):121-9. PubMed PMID: 23385859
  • Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013 Mar;8(3):373-84. PubMed PMID: 23370315
  • Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. PubMed PMID: 23268837
  • Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013 Apr;49(6):1161-8. PubMed PMID: 23265711
  • Christoph DC, Asuncion BR, Hassan B, Tran C, Maltzman JD, O'Shannessy DJ, Wynes MW, Gauler TC, Wohlschlaeger J, Hoiczyk M, Schuler M, Eberhardt WE, Hirsch FR. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol. 2013 Jan;8(1):19-30. PubMed PMID: 23242435
View All (151 Total) View Less

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Specialty Information

Specialties
  • Medical Oncology

General Information

Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;